Got $6,000 to Invest? 3 Unbelievably Cheap Value Stocks to Own for the Next 5 Years

Bausch Health Companies Inc. (TSX:BHC) and Spin Master Corp. (TSX:TOY) are two great contrarian value stocks to buy for the roaring 2020s.

| More on:
Value for money

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

If you’ve got $6,000 in TFSA (Tax-Free Savings Account) cash to invest for the long term, you’ve come to the right place. Investors are rattled over rising U.S. bond yields, which has spelled bad news for tech stocks, especially the high-flying ones that are not yet profitable. In this piece, we’ll look at three value names that appear too cheap for their own good.

Without further ado, consider IA Financial (TSX:IAG), Bausch Health Companies (TSX:BHC), and Spin Master (TSX:TOY).

IA Financial: A well-run insurer at a bargain-basement price

IA Financial is a cheap Canadian insurance and non-bank wealth manager that ought to be scooped up here. The stock surged 72% off its March 2020 depths but remains the name still remains too cheap to ignore, given the calibre of business you’re getting. The stock sports a bountiful 3% yield, which, while lower than its Canadian insurance peers, is well covered, with more room to run over the next five years and beyond.

At the time of writing, the stock trades at 0.4 times sales, 3.8 times cash flow, and 1.1 times book value, all of which are still lower than the stock’s five-year historical average multiples of 0.5, 11.6, and 1.2, respectively.

Bausch Health Companies: Activist investor Carl Icahn’s involvement could propel shares in a post-COVID environment

Bausch Health Companies is a Canadian biopharmaceutical company with a brilliant management team. Led by CEO Joe Papa, the company has moved on from its days as the infamous Valeant Pharmaceuticals and its debt-fueled acquisition spree.

Papa has done a terrific job of trimming away at the mountain of debt while injecting cash into innovative health solutions. And with activist investor Carl Icahn jumping on board to help enhance shareholder value, I think investors should think strongly about loading up on shares on any meaningful dips.

The stock is still modestly-valued at 1.44 times sales and 7.2 times next year’s expected earnings.

Spin Master: Canadian toymaker comes roaring back

Spin Master made headlines last week, with the company reporting much better-than-expected earnings that sent shares soaring over 44%.

The company made major strides in the fourth quarter, solving serious supply chain issues that weighted down its prior quarters. The company saw its pretty flat net sales, with revenues inching up just under 4%. Adjusted EPS numbers were at $0.14, doubling that of consensus estimates calling for $0.07. The biggest takeaway from the quarter, I thought, was the profound strength in the digital game revenues, which skyrocketed over 400% to US$31.8 million.

Optimistic management expectations also provided rally fuel for the stock, and it may very well just be a preview of what’s the come as “the roaring 2020s” look to take hold over the next five years. In any case, the stock remains way too cheap here after its blowout quarter. The stock trades at a mere two times sales at the time of writing.

Sell-side analysts hiked their price targets after the fact. Most recently, RBC Capital Markets hiked its rating on Spin Master from sector perform to outperform, with a massive $10 upgrade to $44, representing another 25% worth of upside from today’s levels.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Bausch Health Companies. The Motley Fool owns shares of and recommends Bausch Health Companies and Spin Master.

More on Coronavirus

little girl in pilot costume playing and dreaming of flying over the sky
Coronavirus

Air Canada Stock: How High Could it go?

AC stock is up 29% in the last six months alone, so should we expect more great things? Or is…

Read more »

eat food
Coronavirus

Goodfood Stock Doubles Within Days: Time to Buy?

Goodfood (TSX:FOOD) stock has surged 125% in the last few weeks, so what happened, and should investors hop back on…

Read more »

stock data
Tech Stocks

If I Could Only Buy 1 Stock Before 2023, This Would Be It

This stock is the one company that really doesn't deserve its ultra-low share price, so I'll definitely pick it up…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Air Canada Stock Fell 5% in November: Is it a Buy Today?

Air Canada (TSX:AC) stock saw remarkable improvements during its last quarter but still dropped 5% with more recession hints. So,…

Read more »

Airport and plane
Coronavirus

Is Air Canada Stock a Buy Today?

Airlines are on the rebound. Does Air Canada stock deserve to be on your buy list?

Read more »

A patient takes medicine out of a daily pill box.
Coronavirus

Retirees: 2 Healthcare Stocks That Could Help Set You up for Life

Healthcare stocks offer an incredible opportunity for growth for those investors who look to the right stocks, such as these…

Read more »

sad concerned deep in thought
Coronavirus

Here’s Why I Just Bought WELL Health Stock

WELL Health stock (TSX:WELL) may be a healthcare stock and a tech stock, but don't let that keep you from…

Read more »

healthcare pharma
Coronavirus

WELL Stock: The Safe Stock Investors Can’t Afford to Ignore

WELL stock (TSX:WELL) fell 68% from peak to trough, and yet there's no good reason as to why. So now…

Read more »